Results 51 to 60 of about 17,785 (168)

PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer

Exploration, EarlyView.
Advanced prostate cancer is highly invasive and prone to rapid metastasis, creating an urgent need for novel therapeutic strategies. We developed a PSMA‐targeting macrophage membrane‐coated nanomedicine (P‐MMCNPs@DM1). Leveraging the immune‐evasive and active‐targeting properties of macrophage membrane coating, P‐MMCNPs@DM1 effectively managed both ...
Keying Zhang, Bo Gao, Jingwei Wang, Yu Li, Chao Xu, Fa Yang, Shaojie Liu, Hongji Li, Chao Zhang, Xiangliang Meng, Zhaokun Shi, Rui Zhang, Ruili Zhang, Zhongliang Wang, Weihong Wen, Qiang Zhang, Yuankang Zou, Donghui Han, Huijie Bian, Weijun Qin   +19 more
wiley   +1 more source

Metal-Based PSMA Radioligands [PDF]

Molecules, 2017
Prostate cancer is one of the most common malignancies for which great progress has been made in identifying appropriate molecular targets that would enable efficient in vivo targeting for imaging and therapy. The type II integral membrane protein, prostate specific membrane antigen (PSMA) is overexpressed on prostate cancer cells in proportion to the ...
Eleni Gourni, Gjermund Henriksen
openaire   +3 more sources

Strategic construction of fluorinated surroundings in NIR‐II‐emissive organic semiconducting agents for amplifying cancer phototheranostics

FlexMat, EarlyView.
The development of conventional phototheranostic nanomedicines suffers from an intrinsic trade‐off between NIR‐II fluorescence emission and phototherapeutic effects, leading to poor overall efficacy. Herein, we propose an innovative fluorination strategy by constructing fluorinated surroundings in NIR‐II‐emissive organic semiconducting agents to ...
Xiaoming Hu, Achen Qin, Caijun Zhu, Jinshuo Mi, Zejing Chen, Jiaying Shao, Zhen Li, Zhen Yang   +7 more
wiley   +1 more source

⁶⁸Ga-PSMA PET/CT in Recurrent Prostate Cancer after Radical Prostatectomy Using PSMA-RADS Version 2.0

Diagnostics
Background: 68Ga-PSMA PET/CT is superior to standard-of-care imaging for detecting regional and distant metastatic recurrent prostate cancer. The objective of our study was to evaluate the performance of 68Ga-PSMAPET/CT in our patient population, using ...
Gabriele Masselli, Saadi Sollaku, Cristina De Angelis, Elisabetta Polettini, Gianfranco Gualdi, Emanuele Casciani   +5 more
doaj   +1 more source

Australian Society of Medical Imaging and Radiation Therapy Image Registration in Radiation Therapy Position Paper

Journal of Medical Radiation Sciences, EarlyView.
The ASMIRT Image Registration Working Party outlines the critical role of radiation therapists in performing, assessing and documenting rigid and deformable image registration across treatment planning, delivery and adaptive workflows. The position paper emphasises consistent nomenclature, robust QA processes, strong collaboration with diagnostic ...
Tamara Barry, Huong Nguyen, Laurel Schmidt, Kate Stewart, Nigel Anderson   +4 more
wiley   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Contemporary Management of Malignancies of the Parotid Gland: A State‐of‐the‐Art Review

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objectives To provide a systematic update on the contemporary management of malignancies of the parotid gland (MPG), focusing on evidence‐based practices and emerging therapeutics. Data Sources PubMed literature search. Review Methods A search protocol was designed according to the Preferred Reporting Items for Systematic Reviews and Meta ...
Anthony Tang, Vanessa Helou, Shaum S. Sridharan, Renata Ferrarotto, Jessica L. Geiger, Dan P. Zandberg, Diana Bell, Heath Skinner, Matthew E. Spector, Eugene N. Myers, Kevin J. Contrera   +10 more
wiley   +1 more source

In-silico study of thiazolidinone-linked Glu-Ureido based PSMA ligands for PET application

Discover Chemistry
Introduction The Prostate Specific Membrane Antigen (PSMA) is a type II transmembrane glycoprotein known as Glutamate Carboxypeptidase II, overexpressed in prostate carcinoma.
Mohd. Faheem, Vaibhav Pandey, Manisha Prasad, Manish Dixit   +3 more
doaj   +1 more source

PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression

Molecular & Cellular Oncology, 2017
Increased Prostate Specific Membrane Antigen expression promotes tumor progression in prostate epithelium by dysregulating the β1-integrin/type I insulin-like growth factor receptor axis, resulting in a shift in signaling from the less aggressive mitogen-
Leslie Ann Caromile, Linda H. Shapiro
doaj   +1 more source

A Pilot Study of 18F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease

The Prostate, EarlyView.
ABSTRACT Introduction PSMA‐PET offers an opportunity to reduce the mischaracterization of disease in active surveillance (AS) and focal therapy (FT) candidates. We describe the results of a pilot clinical trial evaluating 18F‐radiohybrid(rh)PSMA‐7.3‐PET/MRI to detect occult adverse pathology among potential AS and FT candidates (NCT05852041).
Ridwan Alam, Derek Hesse, Nikki Hubbard, Emma McGarrity, Sai Kumar, Clayton Neill, Yutai Li, Nicole Handa, Hiten D. Patel, Edward M. Schaeffer, Hatice Savas, Ashley E. Ross   +11 more
wiley   +1 more source